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Because peripheral vasoconstriction impairs cardiac pe 
mance in chronic heart failure ( I), vasodilater therap 
emerged as an e! ‘ablished approach to the treatment of this 
disorder. The administration of drugs that &ate peripheral 
arteries and veins produces ~emodynamic 
improvement in patients with heart failure 
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term treatment with vasodilators s been shown to reduce 
the mor!ality of this disease (2,3j. wever, currently avail- 
able vasodilator drugs have important limitations 
vasodibrs fail to produce long-term ~~mody~am~c 
because tolerance develops to their initial hem0 
effects (4-6). Others activate ne~~o~ormo~a~ ~ec~a~~s~s 
and cause fluid retention that may limit their sym~t~~at~c 
and prognostic benefits (3.7). Still others depress myocardial 
contractility and may thereby worsen the clinical condition 
of patients (8). Finally. most vascdilator dtqs prod~cc 
cts that resirict rhe usetulness of long-term 
an is a. new vasodikator drug that acts by irilcr- 
fering with the inosit~~-tr~p~~§~~a 
way, an important mechanism of 
drug is orally active and has a I 
permits once-daiiy dosing (IO). 
arteries and veins (1 I), flosequinan produces short- (12) and 
long-term hemodynamk benefits in hcF fa~?ure (B&13!: 
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tolerance has not been reported uring prolonged therapy. 
Furthermore, flosequinan has been well tolerated in early 
clinical studies. The drug does not cause tluid retention r 
depress cardiac contractility (14); thus, its use has not been 
associated with worsening heart failure. Flosequinan has 
produced clinical benefits in two small controlled trials 
(15,162, but its effect on symptoms and exercise to!erance 
has not been evaluated in large scale studies. 
We therefore carried out the Randomized Evaluation of 
FLosequinan on ExerCise Tolerance (REFLECT) study. 
The primary objective of this trial was to assess the effect of
flosequinan on symptoms and exercise capacity in a large 
group of patients with chronic heart failure who remained 
symptomatic despite treatment with digitalis and diuretic 
drugs. 
Patients with chronic heart failure were enrolled at 23 
centers in the United States and Canada. Heart failure was 
defined by the presence ofdyspnea or fatigue on exertion i
association with a left ventricular ejection fraction 540% 
and a cardiothoracic ratio ~50%. All patients had subjective 
and objective evidence for reduced effort tolerance, as 
demonstrated by New York Heart Association functional 
class II or III symptoms and an exercise duration (modified 
Naughton protocol) between 3 a d 14 min despite treatment 
with digitalis and diuretic drugs for ~2months. The use of 
other vasodilators (tong-acting nitrates, hydralazine, pra- 
zosin, converting-enzyme inhibitors or calcium channel 
blocking agents) was not permitted, but treatment with 
antiarrhythmic drugs other than beta-adrenergic blocking 
agents was allowed. Patients could not participate if they had 
a primary valvular or pericardial disorder or obstructive er 
hypertrophic cardiomyopathy. Patients were also excluded 
if they had any of the following: age ~18 years; systolic 
blood pressure ~90 mm Hg; exercise limited by angina, lung 
disease or claudication; angina requiring continuous treat- 
ment: a myocardial infarction within 3 months, or severe 
primary pulmonary, renal or hepatic disease. The protocol 
was approved by the Institutional Review Board of all 
participating institutions. 
At the start of the study, patients were queried about heir 
symptoms; vital signs were measured; cardiac size and 
function were determined (by chest radiography and 
radionuclide ventriculography, respectively); cardiac ar- 
rhythmias were quantified (bya 24-h ambulatory ecording), 
and blood w;\s collect,sd fo:r the evaluation f serum electro- 
lytes, renal function an!9 circulati neurohormonal f ctors. 
In addition, patients ~~~~~e~e~t r,:peated maximal treadmill 
exercise testing (using a modified Naughton protocol) until 
exercise times limited by either dyspnea or fatigue were 
h@ly’ reproducible; specifically, the durations of three con- 
secutive tests wzre required to he within 60 s of each other 
and show no trend. ‘1Zrs criterion for reproducibility has 
been shown to minimize the placebo elect that is commonly 
observed incontrolled trials in heart $ure ~~~~s~y Dl et al., 
uapublished observations). At selected centers, exercise 
tolerance was also assessed bg the evaluation of oxygen 
consumption using breat eas~reme~ts of ex- 
either flosequinan (1 
placebo, in addition 
months. This dose of 
exercise tolerance 
respectively. Every e 
comitantly administered cardioactiv 
closes of diuretic drugs could be a 
increased >2 kg, Patients were not permitted toreceive open 
label ~oscq~i~a~. At the end of the study, all assessments 
carried out at the start of the study were repeated. 
aIysis. The primary objective of the study, 
the original protocol, VJ~S 
change in exercise tolerance i  the placebo a 
treatment groups after 12 weeks of thera 
was estimated tobe 150 patients based 
that he difference in the exercise response 
groups would be 60 s with an SD of 75 s (power = 0.80, 
alpha = 0.05). 
The ~ase~~~e c~a~a~te~$t~~s of the two treatment groups 
were compared by the f test (for continuous variables) and 
the Fisher exact est (for categorical variables). Treatment 
effects were assessed by comparing the change in one group 
with the change in the other. Aoal;lses were carried out on 
all available da&a (using carry forward methods) according to 
the patients’ original randomized ~ss~~rneot (intention to 
treat princil+). Comparisons were performed by analysis of
variance (Tables 2 and 3) or Fisher exact est (Table 4, Fig. 
3). Appropriate nonparametric methods (the median test 
1171) were used when the data displayed marked nonnormal- 
ity (Fig. 1). General linear models for categorical data were 
used for the analyses in Figure 2. 
Patient groups. One hundred ninety-three patients (168 
men, 25 women) were enrolled in the REFLE 
cause of heart failure was iscbemic heart 
patients and idiopathic ardiomyopathy in 109; 81 patients 
had class II and 112 patients had class III symptoms. The 
mean left ventricular ejection fraction was 0.26. All but five 
patients were receiving digoxin, un the mean dose sf 
furosemide prescribed was 88 mg daily. Within 4 weeks of 
enrollment, 27% of patients had received a converting en- 
zyme inhibitor, which was discontinued at least 2 weeks 
before ntry into the study. 
aseline Characteristics of Patktnts 
Placebo FPosequinan 
(n = totIp trt = 93) 
Demographic characteristics 
Age (yr) 57.2 i 1.3 58.2 2 I.1 
Male/female KY/?3 81,12 
Weight (kg) 82.2 2 2.1 82.1 5 2.1 
Cause of heart failure 
kchemic heart disease 46 38 
Primary ~~rd~omyo~t~y 54 55 
Concomitant medications 
Digoxin use (95) 96 96 
Daily dose of furosemide (mglday) 9024 88 i- 7 
Prior treatment with nitrates (%) 34 25 
Prior treatment with hydraiarine (‘%) 4 6 
Prior treatment with ACE inhibitors (5%) 28 26 
Hemodyneaic measureme.its 
Cardiothoracic ratio 0.60 + 0.01 0.60 + 0.01 
LV ejection fraction O.i6 i: 0.01 0.25 It 0.01 
Supine systolic blood pressure (mm Wg) 123 + 3 125 + 2 
Supine diastolic blood oressure (mm Hg) 76 2 I 79 2 I 
kleart rale (hea!s/minb $2 -c 2 80 2 1 
Functional measurements 
NYHA functional class tII/IBP) 42158 39154 
Exercise duration (s) 520 2 17 536 t I8 
Maximal oxygen consumption (ml/kg per mitt) i4.2 ? 0.9 !lS ? 0.9 
Biochemical measurements 
Serum sodium concentration (mEq/hter) 139 + 0.3 140 f 0.4 
Serum potassium concentration ~mEq/hterr 4.2 -t- 0.1 4.2 lr. 0.1 
Mood urea nitrogen irngidii 20 + i 21 2 P 
Serum creafinine concentration (mg’dl) 1.4 2 0.03 1.4 2 0.04 
Neurohormonat measz-ements 
Plasma norepinephriae (pglmlr 338 -t 42 378 k 43 
Plasma rmi~ activity @g/m! h) per 4.3 k 1.8 4.1 t 0.9 
Plasma arginine vasopressin (pg/ml) 3.4 i 0.5 2.8 + 0.3 
Plasma atriat natriuretic peptide (pgiml) 140 k 19 114 + I? 
Electrocardiographic measurements 
62 54 
Patients with ventricular tachycardia (5%) 71 74 
- 
*No ditTerences between groups were staiisiically signikant. Data are expressed as niimber or rercerri “* ,.F 
patients or mean value + SE?& Neurohormonal, ambulatory, electrocardrographic and oxygen CO %mption 
measurements were obtained in SS, 81 and 47 patients. respectively. ACE = angir.,;ensin-conveair;a enay~m : LV = 
left ventricular: NYMA = New York Heart Associath; VI% = ventricular premature beats. 
64 
tients, 93 were randomly assigned to 
were assigned to placebo. The two groups 
respect to aPI pretreatment variables (Table 
I), including age, gender, cause and severity of beast failure, 
uoninvasive measures of cardiac function, exercise duration, 
vitai signs, use ofdigoxiu aud diuretic drugs and prior use of 
crmvertiug e 
Ai! but four 
daily or placebo; fo
therapy) received 75 tug once daily 
enced dizziness or tachycardia, or 
100 mg. Of the 193 randomized patients, g patients (2 
receiving placebo, 6 receiving tlosequinan) were withdrawn 
from the study before the first double-blind sythzpFnr* nssess- 
ment at 2 weeks; and 21 patients (9 receiving placebo, 12 
double-b!ind exercise toYermc~ test 
whereas safety was evaluate4 is all I93 
were assessed in !a5 patiei:ts (98 re 
receiving fiosequinan) and exersC;se tol 
12 weeks, exercise tderance increase 
portion of patients iu each group who bad a favorable 
exercise response, defined as au increase irr exercise dura- 
tion of r60 s, r!N s or ri2G s G;‘LZ ~~~t~~~~~e~t values. 
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Figure 1. Median duration of treadmill exercise (modified Naughton 
protocol) in the fosequinsn and placebo groups at the time of 
randomization (0 weeks) and after 4,8 and 12 weeks of double-blind 
therapy. After 12 weeks the median change inexercise duration i
the flosequinan group (closed squares) was ignificantly greater than 
the median change in exercise duration in the placebo group (Q 
circles) (+% vs. t-47 s; p = 0.022). 
RegardlecYs of which criteria are used, there .re more 
respondt:rs in the flosequinan group than in thz placebo 
group (p < 0.0s for all three criteria). When exercise 
capacity was assessed by the measurement of res+atory 
gas exchange, maximal oxygen consumption i creased by 
1.7 ml/kg per min in the flosequinan group (n = 17) but by 
only 0.6 ml/kg per min in the placebo group (n -= 23), p = 
0.05 comparing the two groups. 
The effect of fiosequinan on exercise capacity was not 
Figure 2, Proportion of patients in the placeho group (clear bars) 
and in the flosequinan group (sh bars) who had a favorable 
exercise response, d fined by three different criteria: I) an increase 
in exercise duration ~60 s over baseline: 2) an increase in exercise 
duration 290 s over baseline; and 3) an increase in exercise duration 
~120 s over baseline. Regardless of which criterion was used, the 
proportion of responders was greater in the flosequinan group than 
in the placebo group (all p < 0.05). 
60 - _. ----_ 
P = 0.03 P = 0.002 P = 0.02 1 
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Figure 3. Proportion of patients who reporte :essening of symp- 
toms of heart failure and enhanced oven!1 sense of well-being in the 
Rosequinan group (closed sq~res) and in the placebo group (&pen 
circles) after 2, 4, 6, 8, 10 and 12 weeks of double-Baird therapy. 
After I2 weeks, 55% of patients in the Rosequinan group but only 
36% of the patients in the placebo group had clinical improvement, 
p = 0.018. The time course of improvement in symptoms closely 
paralleled the time course of improvement in exercise tolerance 
(compare Fig. I and Fig. 3). 
dependent on the patient’s pretreatment f~~ctio~a~ class or 
left ventricular ejection fraction. The placebo-corrected in- 
crease in exercise time produced by csequinan was similar 
in patients with class Ii or class III symptoms (t58 and 
i-46 s, Fe~~c~t~~e~y~ and in p+:e ~,nts with an ejection fraction 
rO.20 or >0.30 (+X2 and t49 L, respectively). 
on symptoms of heart ~~it~re. IMing the 1st 2 
we double-blind therapy, a similar proportion (25% to 
30%) of patients in the two treatment groups improved 
clinically. However, after 4 to 12 weeks of therapy, more 
patients io the dosequi>an than in the placebo groilp were 
considered by the iuvestigator to have symptomatic m- 
provement and to show an enhanced overall sense of well- 
being (Fig. 3). The pattern of improvement in the clinical 
status of patients paralleled the pattern of improvement in 
their exercise tolerance (compare Fig. 1 and 3). At the end of 
the study, 55% of patients receiving flosequinan but only 
36% of patients receiving pIacebo benefited from treatment 
(p = 0.018). In addition, 19% of patients receiving placebo 
but only 10% of patients receiving flosequinan had worsen- 
ing heart failure that was sufficiently severe to require an 
increased ose of diuretic drugs or withdrawal from the 
study (p = 0.07). Flosequinan produced no change in func- 
tional class, cardiothoracic ratio or left ventricular ejection 
fraction (Table 2). 
t on ty. Compared the changes een in the 
pla gro long-term the with ~oseq~~~an was 
associated with a significant decrease in supine systolic 
blood pressure (-7 :-.jrn Hg) and increase in supine and 
standing heart r&e (1-8 and +7 beats/min, respectively), 
both p < 0.05, without a change in standing systolic blood 
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Effect of Flosecyinan on Hwd~+nmi:~ ~eas~re~e~~s in Ps2ienrs 
-- .- - ___. ________ -- 
Placebo F$osequinan 
Easeline %WltlTWd Baseline TreaEmnen: p Value _ p_ -_I_- -- -.- 
Supine systolic blood pressure (nm Hg) 122 ? 2 12s T ? I24 I! 2 1x1: 0.02 
Sui ine diaslolic blood pressure mnni iBg) 75 f I 79 x I 79 -c B 77 Yt ? I% 
Supsne heart rate (beats/min) 84 f 2 82 JT 2 82 5 2 88 c ?. 
Standing systolic blood pressure !mm Wg) I?! f 2 124 It 2 123 -+ 2 ii? 5 2 NS 
Standing diastolic blood pressure (mm WgP 79 ? I 79 + I i8 : j 77 r i 
Standing heart rate (beats/min) 88 +_ 1 86 + I 87 + 2 92 + 2 
Body weight (kg) 82 rt 2 83 ? 2 82 ir 2 82 r 2 NS 
Cardiothoracic ratio 0.59 +_ 0.01 0.57 2 0.08 0.60 r 0.01 5.57 2 O.O! NS 
LV ejection fraction 0.28 f 0.02 0.30 ? 0.02 0.25 ‘- 0.02 0.24 0.01 + NS - -. 
Ail values are expressed as mean value 2 SE!+& Data xe shown only for patients with both prerreatment and posttreatment values. Paired data for c:ardiotbomcic 
ratio :,nd left ventricular (P-V) ejection haclion were co!le&d in 147 and 30 patients. respectively. p value denotes significance ai: between-group diEerences. 
pressure or supirie or st~~~dj~g diastdic blood pressure 
ed no si~~i~~a~t changes in 
prL!ssure. 
patients treated wi 
was associated wi 
rine (s, = 0.08) withormt 
associated with any prom mic effects. As assessed hy 
cri:eria rmdiEed from time proposed by ~~~~~a~~~t~ et al. 
(181, ~~~a~~yt~~ia was observed in six patients receiving 
placebo and four patients receiving 
The fr-squency of reported side 
similar in the two treatment g-0 
reactions attributable to peripkral vas~d~lat~~~ (headache. 
dizkess, ~a~~~tati~~ and tac~y~a~d~a~ were more com~fim 
in ~Qse~~~~a~-?reate patients, but only the fr 
headaches was si~~i~~a~t~y different (22% wish 
rapy, eighi patients 
two in the placebo 
n in seven pa?ienis (tive in Ihe 
ticn. One additional patient 
xddenly within 12 weeks of randomi 
oscurrc6 16 days after W~i~~~~~~~~~ frcm 
atment with an anrtiar- 
the protoco$ . Iierice, 
Table 3. Effect of Flosequinan on biochemical and Ncuroho:mor,~. 4 Meascnmerrts ir? Fetimts Wit?! Chronir Hem Fai!ure 
- 
Placebo Flosequinan 
-__- p- 
Baseline Treatment Baseline Treltmenl p va:uc 
- ~_.________ _____~ -- _..~. ---I_-. ~ ___~_. .__--~-- 
Serum sodium concentration (mmollhter) 139 +_ 0.3 139 +_ 0.4 r40 t 0.4 s33 t 0.4 NS 
Serum potassmm concenlratioo (nlmollliti+ 4 ? + 0.I 4.1 + 0.: 4.2 I 0.1 79 5 0.1 hS 
Blood urea nitrogen (mg/dl) 20 I I 20 2 I 21 2 i ?lJ + 1 Ids 
Serum credtinine concentration (mgldl) 1.4 .’ 3.0t 1.4 t 0.04 I.4 t 0.04 1.5 t- 0.04 NS 
Serum cholesterol (mgldl) 214 ? 5 513 ” s 207 t 5 208 2 5 NS 
Total bilirubin (mddl) 0.: + 0.04 0.9 ir 0.04 0.8 t 0.95 0 7 t 0 06 0.03 
Alkaline phosphatase (mUmI) 91 +4 88 f 4 92 + .s 9O*s NS 
Serum aspartate aminotransferase MJlml) 24 f 1 24 z? 1 22 k I 23 * i I P-6 
Serum alanine aminotransferase (mU/ml) 25 * 2 23 ? 1 20 + I jr)” I NS 
Hemcglobin (mEldI) 14.1 2 0.2 14.3 I 0.2 84.3 + 0.2 14.0 5 0.2 NS 
White blood colrnt (X iO~/ml) 7.2 2 0.2 1.3 ?z 0.2 7.2 3 0.2 6 9 Y! 0.2 NS 
Plasma norepinephrinc (pgM) 337 ?r 43 319 f. 38 4LX 1. Q 4% 1 51 ox!? 
Plasma renin activity (mg/ml h) per 4.6 t- I.9 4.8. -c 2.1 4.6 + I.0 5.4 + 1.2 WS 
Plasma argilaine vasopressin (&ml) 3.5 ” 0.5 2.8 c &4 2.1 r 0.3 2.8 c 0.3 NS 
Plasma atrial natriuretic peptide (pg/ml! 133 f 18 IiS c I8 112 5 13 88% II NS 
- - 
p value denotes significance of between-group Merences. 
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Table 4. Adverse Events During the Study 
Placebo Fiosequinan p 
(n = 100) (n = 93) Value 
At least one adverse effect (%) 
Cardiopulmonary symptoms (%I 
Angina 
Dizziness/vertigo 
Edema 
Hypotension 
Palpitation 
Myocardial infarction 
Syncope 
Tachycardia 
Noncardiopulmonary symptoms (c/o) 
Anorexia 
Cough 
Dianhea 
Headache 
Nausea 
Rashlpruritus 
Taste disturbance 
68 
0 (0) 
5 (5) 
7 (7) 
0 (0) 
3 (3) 
2 (2) 
0 (0) 
0 (0) 
l(I) 
4 141 
4 (4) 
9 (9) 
I(I) 
4 (4) 
0 (0) 
71 
1 (1) 
IO (11) 
2 (2) 
2 (2) 
7 (7) 
3 (3) 
1 (1) 
4 (4) 
3 (3) 
2 (2) 
3 (3) 
20 (22) 
6 (6) 
0 (01 
2 (2) 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
MS 
NS 
NS 
0.04 
NS 
NS 
NS 
Data are expressed as number (%) of patients. 
The results of this multicenter, placebo-controlled study 
indicate that flosequinan produces clinical benefits when 
administered to patient!: with zhromc heart failure who 
remain symptomatic despite treatment with digitalis and 
Table 5. Reasons for Withdrawal From the Study During Double- 
Blind Therapy 
Placebo Flosequinan 
(n = 100) In = 93) 
Worsening heart failure IO 6 
Acute myocardial infarction I 2 (I*) 
Chest pain syndrome 0 I 
Ventricular arrhythmia 0 I 
Bradycardia I 0 
Sudden death 2 (2*) 5 (5*! 
First dose hypotension 0 I 
Cardiac transplantation I 0 
Flulike syndrome I 0 
Noncardiopulmonary events 
Protocol violation 6 4 
Noncompliance 2 2 
Patient request 3 0 
Administrative reasons 3 3 (I**) 
Hendache I I 
Leg problems I 2 
Hemolytic anemia I 0 
Total 33 28 
*Number of pitient:: who died by intention to treat analysis. Eight of the 
&nine deaths (seven sudden and one after an acute myocardial infarction) 
occurred during double-blind therapy. tone patient died suddenly 16 days 
after MM~~wI from the study for administrative reasons; the patient 
required treatment x%h an ant&rhythmic drug that was prohibited by the 
protocol. 
diuretic drugs. Flosequinan enhanced th 
tus and well-being af patients in our stu 
risk of worsening heart 
capacity as assessed by e 
exercise or the measurement of maxi 
tion. Finally, flosequinan was subjectively well tolerated by 
the patients in our study.. Although some patients experi- 
enced side effects attributable to the drug’s vasodi:ator 
actions, these were mild and short-iived and generally di 
not require disco~tifl~ation of therapy. The incident 
laboratory abnor 
placebo treatme~ 
associated with m 
proarrhythmia or fluid r 
of other drugs for hear 
scale study confirm the results of s 
have shown that flosequinan is an effective treatment for 
chronic heart failure. 
to those previously report 
converting enzyme inhibitors in chronic heart failure (l9- 
?.I). Both flosequinan and the converting enzyme inhibitors 
are effective in patients in functional class II or III who 
remain symptomatic despite therapy with digoxin 
uretic drugs. Both flosequinan and the converting 
inhibitors alleviate th symptoms of heart failure, and this 
benefit s paralleled by a similar increase inexercise capacity 
(approximately 50 to 60 s using a modified Naughton proto- 
ith both classes ofdrugs, the improvement i  
exercise tolerance is not seen immediately after the institu- 
tion of therapy but becomes apparent only after patients are 
treated for several months (Fig. 1); the pathophysiologic 
mechanisms underlying this delay are not understood 
(19,21). Because of these similarities, flosequinan may be 
useful in patients who cannot tolerate or shou! d not receive 
converting enzyme inhibitors, because of the drug is not 
associated with many of the side effects of the converting 
enzyme inhibitors (such as first-dose hypotension, cough, 
rash or renal insufficiency). 
The responses toflosequinan also resemble the responses 
seen with the combination of hydralazine and isosorbide 
dinitrate in patients with chronic heart failure. Both flose- 
quinan and the combination of hydralazine and isosorbide 
dinitrate produce similar hemodynamic effects (12,13,22,23). 
This response isprimarily the result of a direct dilating effect 
of these drugs on peripheral arteries and veins, although 
both flosequinan and hydralazine also exert direct positive 
inotropic and chronotropk effects (14,24,25). Both flose- 
quinan and the vasodiiator c mbination have been shown to 
improve the symptoms and exercise tolerance of patients 
with heart failure in controlIed clinical trials (3,15,16). 
ever, the administration of flcsequinan is more convenient 
and may be subjectively better tolerated than the combina- 
tion of isosorbide dinitrate and hydralazine. Whereas the 
vasodilator combination requires multiple dosing each day 
kinase C pathway, because the d 
in both of these ~~trace~~~~a,r seco 
exposure to endogenous vasoco~stnctors 
example) (9). Such a mechanism of action may be 
among Bnically available vasodilators. 
that of converting enzyme inhibitors or a combioat~o~ of 
and isosorbide dirritrate, 
sequinan to prolong life in 
owever, in the doses use 
au’s vasodilator properties (29), and these actions are char- 
acteristic of drugs that have an adverse 
(30,31). Concerns that flosequinan might adversely affect 
mortahty are heightened by the finding in the present study 
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